Browse studies

Find your next paid study

27,293 recruiting studies available now

Pilot Trial of Olutasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients Carrying IDH1 Mutation With AML, MDS, or CMML Disease

This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergo…

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT06543381

Phase 2

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a typ…

Early Alzheimer's Disease

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07033494

Observational

Neuromuscular Electrical Stimulation: A Novel Treatment for Improving Metabolism

Once written consent is obtained, the participant will be provided with an accelerometer to be worn for 7 days to assess current physical activity levels. Subj…

Insulin Resistance

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Texas, El PasoNCT06722391

Phase 3

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal jun…

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Phase 2

Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)

This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchang…

Idiopathic Pulmonary Fibrosis

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of Alabama at BirminghamNCT07674745

Phase 1

A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-…

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07356154

Phase 2

A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) i…

Crohn's DiseaseUlcerative Colitis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AbbVieNCT07697456

Phase 1

A Phase I Trial of Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Background: T-cell lymphoma is a blood cancer that affects immune system cells. People tend to survive less than 1 year if this disease does not respond to tr…

Lymphoma, T Cell, PeripheralT-cell LymphomaAngioimmunoblastic T-cell Lymphoma+3 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07388563

Phase 1

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biolo…

Locally Advanced / Metastatic Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Crescent Biopharma, Inc.NCT07335497

Phase 2Remote eligible

An Internet of Things Automated Cognitive Behavioral Therapy for Insomnia That Improves Cognition in Older Adults

This double blind randomized clinical trial on older independent-living healthy individuals with symptoms of insomnia will harness Cognitive Behavioral Therapy…

InsomniaInsomnia Chronic

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Proactive Life IncNCT07316153

Phase 3

A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)

This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hemat…

Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis

Estimated

~$50 – $1,350

Actual pay is set by the research site.

National Institute of Allergy and Infectious Diseases (NIAID)NCT04047628

Phase 3

A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.

A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal …

Subcutaneous Fat

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Caliway Biopharmaceuticals Co., Ltd.NCT07526974